EntreMed, Inc. has been granted a U.S. Patent No. 7,012,070 covering methods of treatment for a broad range of indications with its lead clinical-stage compound, 2-methoxyestradiol (2ME2). Patent No. 7,012,070 which is entitled “Estrogenic Compounds as Anti-Mitotic Agents,” includes claims granted by the U.S. Patent Office covering 2ME2 for the treatment of multiple indications that includes cancer and inflammatory disorders such as rheumatoid arthritis.
Panzem® NCD is the oral formulation of 2ME2 which is currently in Phase 2 clinical trials for cancer, while Panzem® is still in preclinical development for rheumatoid arthritis. The patent is owned by Children’s Hospital Boston and licensed exclusively worldwide to EntreMed, Inc.
Panzem® (2ME2) is a novel anticancer agent, which is part of a next generation of antimitotic cancer drugs that bind to tubulin and work through multiple cellular pathways. 2ME2 can attack tumors on multiple fronts – directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells (mitosis), by inducing programmed cell death (apoptosis), and by blocking blood vessels that feed tumors (angiogenesis inhibition).
According to James S. Burns (EntreMed President & CEO), the company is focused on the development of a new generation of small molecule drugs for the treatment of cancer and inflammatory disorders by attacking disease cells directly and the blood vessels that nourish them. Acquisition of the patent further expands EntreMed’s intellectual property coverage for 2ME2.
Read the complete press release (a pdf file).
.jpg)
Comment Preview